Weight-loss drug studies widen to strokes and knee joints

Novo Nordisk's diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways

Novo's Wegovy weight loss drug: Its active ingredients are being studied around the world.

Denmark's Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Both treatments contain the active ingredient semaglutide, part of a class known as GLP-1 drugs that work by helping to control blood sugar levels and triggering a feeling of fullness.